Unaudited Financial Results for the Half Year Ended 30.09.2025 is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio Limited reported a net loss of Rs 19.56 lakhs for H1 FY26 (ended Sept 30, 2025) versus a Rs 11.66 lakh loss in H1 FY25, with an exceptional item of Rs 19.16 lakhs dragging down results. Revenue from operations stood at around Rs 402 lakhs, up roughly 13.5% from Rs 354 lakhs in the year-ago half year. Total expenses were Rs 423 lakhs and other income was Rs 52 lakhs, giving a small operating profit before the exceptional item. The auditor (MGHVS & Associates) issued an unqualified limited review report. Cash from operations was negative at Rs 32.59 lakhs, but the overall cash position improved to Rs 104.36 lakhs (vs Rs 9.57 lakhs at March 2025) helped by share capital infusion (IPO) and Rs 70 lakhs of fresh long-term borrowing. The company utilised IPO proceeds mainly for plant and machinery purchase (Rs 174.23 lakhs in H1) for the FMCG/freeze-dried products division.
Shareholders should note the widening loss, exceptional charge and negative operating cashflow as concerns, but the recent IPO and ongoing capex on the freeze-dried products plant indicate the company is in an expansion phase, so near-term profitability may remain subdued. Watch for revenue ramp-up from the new capacity and any further exceptional items.